Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ClearPlan

This article was originally published in The Tan Sheet

Executive Summary

Fertility monitor distributed by Unipath Diagnostics reaches drug store shelves the week of March 1, retailing at $199.99 with a $25 introductory rebate. The handheld monitor, which tracks estrogen and luteinizing hormone levels in a woman's urine, cleared FDA Oct. 30 ("The Tan Sheet" Nov. 9, 1998, p. 13). FDA also signs off on a 510(k) Feb. 24 for the company's ClearPlan Data Transfer software that can download up to six months of fertility level and sexual event information from the monitor into a Windows-based format for review by a fertility specialist. The software, which is expected to be available in May through the company, should retail for approximately $100, Unipath says

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel